131 related articles for article (PubMed ID: 25015764)
1. Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer.
Wang L; Lin YL; Li B; Wang YZ; Li WP; Ma JG
J Int Med Res; 2014 Oct; 42(5):1085-92. PubMed ID: 25015764
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.
Lin YL; Sun G; Liu XQ; Li WP; Ma JG
J Int Med Res; 2011; 39(1):179-86. PubMed ID: 21672320
[TBL] [Abstract][Full Text] [Related]
3. Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.
Lin YL; Li YL; Ma JG
Med Sci Monit; 2017 Oct; 23():4895-4900. PubMed ID: 29026066
[TBL] [Abstract][Full Text] [Related]
4. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients.
Widschwendter A; Ivarsson L; Blassnig A; Müller HM; Fiegl H; Wiedemair A; Müller-Holzner E; Goebel G; Marth C; Widschwendter M
Int J Cancer; 2004 Mar; 109(2):163-6. PubMed ID: 14750164
[TBL] [Abstract][Full Text] [Related]
5. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features.
Maruyama R; Toyooka S; Toyooka KO; Virmani AK; Zöchbauer-Müller S; Farinas AJ; Minna JD; McConnell J; Frenkel EP; Gazdar AF
Clin Cancer Res; 2002 Feb; 8(2):514-9. PubMed ID: 11839671
[TBL] [Abstract][Full Text] [Related]
6. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa.
Roman-Gomez J; Castillejo JA; Jimenez A; Cervantes F; Boque C; Hermosin L; Leon A; Grañena A; Colomer D; Heiniger A; Torres A
J Clin Oncol; 2003 Apr; 21(8):1472-9. PubMed ID: 12697869
[TBL] [Abstract][Full Text] [Related]
7. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
[TBL] [Abstract][Full Text] [Related]
8. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease.
Singal R; Ferdinand L; Reis IM; Schlesselman JJ
Oncol Rep; 2004 Sep; 12(3):631-7. PubMed ID: 15289848
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
Padar A; Sathyanarayana UG; Suzuki M; Maruyama R; Hsieh JT; Frenkel EP; Minna JD; Gazdar AF
Clin Cancer Res; 2003 Oct; 9(13):4730-4. PubMed ID: 14581343
[TBL] [Abstract][Full Text] [Related]
10. Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer.
Zhai X; Li SJ
Asian Pac J Cancer Prev; 2014; 15(12):4925-8. PubMed ID: 24998565
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas.
Toyooka S; Toyooka KO; Harada K; Miyajima K; Makarla P; Sathyanarayana UG; Yin J; Sato F; Shivapurkar N; Meltzer SJ; Gazdar AF
Cancer Res; 2002 Jun; 62(12):3382-6. PubMed ID: 12067979
[TBL] [Abstract][Full Text] [Related]
12. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
[TBL] [Abstract][Full Text] [Related]
14. Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer.
Luo ZG; Li ZG; Gui SL; Chi BJ; Ma JG
J Int Med Res; 2014 Feb; 42(1):35-41. PubMed ID: 24366498
[TBL] [Abstract][Full Text] [Related]
15. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
Collard RL; Harya NS; Monzon FA; Maier CE; O'Keefe DS
Prostate; 2006 May; 66(7):687-95. PubMed ID: 16425203
[TBL] [Abstract][Full Text] [Related]
16. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.
Toyooka KO; Toyooka S; Virmani AK; Sathyanarayana UG; Euhus DM; Gilcrease M; Minna JD; Gazdar AF
Cancer Res; 2001 Jun; 61(11):4556-60. PubMed ID: 11389090
[TBL] [Abstract][Full Text] [Related]
17. Relationship between Methylation of FHIT and CDH13 Gene Promoter Region and Liver Cancer.
Tuoya AD; Wang DX; Xing YS; Liu RJ; Hu YX; Zhang MD; Bai TY; Lv XL; Li J; Chang FH
Curr Med Sci; 2020 Jun; 40(3):502-509. PubMed ID: 32474857
[TBL] [Abstract][Full Text] [Related]
18. Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer.
Niu WB; Gui SL; Lin YL; Fu XL; Ma JG; Li WP
Med Sci Monit; 2014 Dec; 20():2584-9. PubMed ID: 25486497
[TBL] [Abstract][Full Text] [Related]
19. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
20. Prevalent hyper-methylation of the CDH13 gene promoter in malignant B cell lymphomas.
Ogama Y; Ouchida M; Yoshino T; Ito S; Takimoto H; Shiote Y; Ishimaru F; Harada M; Tanimoto M; Shimizu K
Int J Oncol; 2004 Sep; 25(3):685-91. PubMed ID: 15289870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
